Cheilitis granulomatosa.
Melkersson-Rosenthal Syndrome (MRS) is a rare syndrome that is characterized by a triad of facial paralysis, chronic edema of the lip, and a fissured tongue. Most commonly, one element of the triad precedes the development of the other symptoms. We present a case of cheilitis granulomatosa (CG) as a manifestation of incomplete MRS. As the etiology remains unknown, treatment of CG is challenging. Intralesional glucocorticoids remain the first-line treatment, but recurrences are common. We discuss alternative treatment strategies that include combination therapy with other anti-inflammatory agents and biologics, such as infliximab.
Department of Dermatology, New York University, New York, New York, USA.
Amy E
AE
Rose
Marie
M
Leger
Julie
J
Chu
Shane
S
Meehan
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001706:Biopsy; D003424:Crohn Disease; D005260:Female; D006801:Humans; D000069285:Infliximab; D015552:Injections, Intralesional; D008012:Lidocaine / Q000008:administration & dosage; D008046:Lip / Q000473:pathology; D008556:Melkersson-Rosenthal Syndrome / Q000175:diagnosis* / Q000188:drug therapy; D013577:Syndrome; D014221:Triamcinolone / Q000008:administration & dosage / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D014221:Triamcinolone; D008012:Lidocaine; D000069285:Infliximab